Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospitals Bristol and Weston NHS Foundation Trust
Incyte Corporation
Incyte Corporation
G1 Therapeutics, Inc.
National Cancer Institute (NCI)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Spanish Oncology Genito-Urinary Group
European Association of Urology Research Foundation
Case Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
Hoosier Cancer Research Network
University of Utah
University of Washington
University of Florida
Astellas Pharma Inc
National Cancer Institute (NCI)
Hoosier Cancer Research Network
University of California, San Francisco
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Hoosier Cancer Research Network
Hoosier Cancer Research Network
Mirati Therapeutics Inc.
University of California, Irvine
OncoNano Medicine, Inc.
pharmaand GmbH
Nektar Therapeutics
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Hoosier Cancer Research Network
UroGen Pharma Ltd.
Duke University
Hoosier Cancer Research Network
Hoosier Cancer Research Network
University of Michigan Rogel Cancer Center
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Acrotech Biopharma Inc.
Acerta Pharma BV
Genentech, Inc.
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
University of Michigan
Dendreon
National Institutes of Health Clinical Center (CC)